The discovery of a new class of large-conductance Ca2+-activated K+ channel opener targeted for overactive bladder: Synthesis and structure-activity relationships of 2-amino-4-azaindoles

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 12, 2003, Pages 2003-2007

  Turner, Sean C ^a   Carroll, William A ^a   White, Tammie K ^a   Gopalakrishnan, Murali ^a   Coghlan, Michael J ^a   Shieh, Char Chang ^a   Zhang, Xu Feng ^a   Parihar, Ashutosh S ^a   Buckner, Steven A ^a   Milicic, Ivan ^a   Sullivan, James P ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 3 NITROPYRIDINE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ION; CROMAKALIM; INDOLE DERIVATIVE; POTASSIUM CHANNEL STIMULATING AGENT; POTASSIUM ION; PYRIDINE DERIVATIVE; RUBIDIUM ION; UNCLASSIFIED DRUG;

ALPHA CHAIN; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; EMBRYO; GENETIC TRANSFECTION; IN VITRO STUDY; LANDRACE; MUSCLE TISSUE; NONHUMAN; OVERACTIVE BLADDER; PATCH CLAMP; SMOOTH MUSCLE; STRUCTURE ACTIVITY RELATION; SWINE;

SUS SCROFA;

EID: 12444281769     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00324-X     Document Type: Article

References (20)

1. Andersson K.-E., Appell R., Cardozo L.D., Chapple C., Drutz H.P., Finkbeiner A.E., Haab F., Navarrete R.V. Brit. J. Urol. Int. 84:1999;923.
2. Urinary incontinence in adults: acute and chronic management. Clinical practice guideline number 2 (1996 Update) AHCPR publication No. 96-0682; March, 996.
3. Wein A. J. Urol. Clin. North Am. 22:1995;557.
4. (a) Nurse D.E., Restorick J.M., Mundy A.R. Br. J. Urol. 68:1991;27
5. (b) Restorick J.M., Nurse D.E. Neurourol. Urodyn. 7:1988;207.
6. (a) Chess-Williams R., Martin S.W., Korstanje C., Chapple C.R. Br. J. Urol. 83:1999;1050
7. (b) Zografos P., Li J.H., Kau S.T. Pharmacology. 45:1992;216
8. (c) Martin S.W., Radley S.C., Chess-Williams R., Korstanje C., Chapple C.R. Br. J. Urol. 80:1997;405.
9. Calderone V. Curr. Med. Chem. 9:2002;1385.
10. Petkov G.V., Bonev A.D., Heppner T.J., Brenner R., Aldrich R.W., Nelson M.T. J. Physiol. 537:2001;443.
11. Coghlan M.J., Carroll W.A., Gopalakrishnan M. J. Med. Chem. 44:2001;1628.
12. Trivedi S., Potter-Lee L., Li J.H., Yasay G.D., Russell K., Ohnmacht C.J., Empfield J.R., Trainor D.A., Kau S.T. Biochem. Biophys. Res. Commun. 213:1995;404.
13. Tanaka M., Sasaki Y., Hukui T., Kyotani J., Hayashi S., Hamada K., Kimura Y., Ukai Y., Kitano M., Kimura K. J. Urol. 159 Suppl. 21:1998.
14. Hewawasam P., Erway M., Thalody G., Weiner H., Boissard C.G., Gribkoff V.K., Meanwell N.A., Lodge N., Starrett J.E. Jr. Bioorg. Med. Chem. Lett. 12:2002;1117.
15. Finch N., Robison M.M., Valerio M.P. J. Org. Chem. 37:1972;51.
16. (a) de-Allie F.A., Bolsover S.R., Nowicky A.V., Strong P.N. Brit. J. Pharmacology. 117:1996;479
17. (b) Daniel S., Malkowitz L., Wang H.-C., Beer B., Blime A.J., Ziai M.R. J. Pharmacol. Meth. 25:1991;185.
18. (a) Buckner S.A., Milicic I., Daza A., Davis-Taber R., Scott V.E., Sullivan J.P., Brioni J.D. Eur. J. Pharmacol. 400:2000;287
19. (b) Buckner S.A., Milicic I., Daza A.V., Coghlan M.J., Gopalakrishnan M. Brit. J. Pharmacol. 135:2002;639.
20. Quast U., Bray K.M., Andres H., Manley P.W., Baumlin Y., Dosogne J. Molecular Pharmacology. 43:1993;474.